Buy4

MapLight Therapeutics, Inc.

MLPT

Total Value

$50.1M

Net $50.1M bought

Filing Date

Aug 18, 2026

1 transaction

Purchases

$50.1M

1 transaction

Trade Summary

On Aug 14, 2026, Catalyst4, Inc., Insider, purchased $50.1M of MapLight Therapeutics, Inc. (MLPT) across 1 transaction. The filing covers Voting Common Stock and reflects net buying of $50.1M. Reported prices ranged from $0.00 to $11.38. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Insider Information

Name: Catalyst4, Inc.
Role: Insider
Location: PALO ALTO, CA

Filing Details

Filing Date: Aug 18, 2026
Transaction Date: Aug 14, 2026
Accession Number: 0001900201-26-000005
Form Type: 4
Net Trading Amount: $50.1M

Non-Derivative Transactions

Date	Security	Shares	Price	Type	Value
Aug 14, 2026	Voting Common Stock	4,400,000	$11.38	Purchase	$50.1M

Derivative Transactions

Date	Security	Shares	Exercise Price	Type	Value
Aug 14, 2026	MLPT derivative	2,928,686	$0.00	Purchase	$293

Want live alerts when Catalyst4, Inc. trades again?

Download Insider Trades to track MLPT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

iOS App Android App

Footnotes

(F1)The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.
(F2)The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%.
(F3)The warrants will not expire until exercised in full.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Catalyst4, Inc.

(Last)

(First)

(Middle)

555 BRYANT STREET #376

(Street)

PALO ALTO

94301

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
MapLight Therapeutics, Inc. [ MLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Voting Common Stock	08/14/2026		P		4,400,000	A	$11.38	25,306,689	I	See footnote⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Warrants (right to buy)	$0.0001	08/14/2026		P		2,928,686		⁽²⁾	⁽³⁾	Voting Common Stock	2,928,686	$11.3799	2,928,686	I	See footnote⁽¹⁾

Explanation of Responses:

1. The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.

2. The warrant is immediately exercisable, however, the warrant may not be exercised if the aggregate number of shares of voting common stock beneficially owned by the reporting person immediately following such exercise would exceed 49.99%.

3. The warrants will not expire until exercised in full.

	/s/ Robert Brown	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Form 4 as rendered by the SEC from accession 0001900201-26-000005.

MapLight Therapeutics, Inc.

Trade Summary

Company Information

Insider Information

Filing Details

Non-Derivative Transactions

Derivative Transactions

Want live alerts when Catalyst4, Inc. trades again?

Footnotes

SEC Form 4

SEC Filing

SEC Form 4